Year Published:

2021 2020 2019 2018

Dec 28, 2021

Dec 25, 2021

Nov 18, 2021

Nov 12, 2021

Nov 9, 2021

Nov 4, 2021

Nov 2, 2021

Oct 19, 2021

Oct 15, 2021

Oct 14, 2021

Oct 1, 2021

Sept 28, 2021

Sept 22, 2021

Sept 2, 2021

Aug 9, 2021

Aug 5, 2021

Aug 2, 2021

Jul 29, 2021

Jul 21, 2021

Jul 1, 2021

Jun 22, 2021

Jun 16, 2021

Jun 3, 2021

May 27, 2021

May 24, 2021

May 12, 2021

May 6, 2021

Apr 29, 2021

Apr 8, 2021

Apr 1, 2021

Mar 30, 2021

Mar 24, 2021

Mar 11, 2021

Mar 4, 2021

Feb 25, 2021

Feb 18, 2021

Feb 11, 2021

Jan 5, 2021

Jan 4, 2021

Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna

Novo Nordisk to Acquire Dicerna

Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly

Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021

Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update

Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021

Dicerna to Report Third Quarter 2021 Financial Results on Nov. 9, 2021

Dicerna Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)

Dicerna Announces Data to Be Presented at American Society of Nephrology (ASN) Kidney Week 2021

Dicerna Announces Poster Presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 in November

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder

Dicerna Announces New Executive Leadership Appointments

Dicerna to Participate in 16th Annual Citi Biopharma Conference

Dicerna Announces Second Quarter 2021 Financial Results and Provides a Business Update

Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria

Dicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021

Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcohol Use Disorder

Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Dicerna Announces Dosing Completion in Nedosiran PHYOX™4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3

Dicerna to Participate in 42nd Annual Goldman Sachs Global Healthcare Conference

Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for LY3819469

Dicerna Announces Boehringer Ingelheim’s Acceptance of Candidate for Development Under RNAi Research Collaboration and License Agreement

Dicerna to Participate in Upcoming Investor Conferences

Dicerna Announces First Quarter 2021 Financial Results and Provides a Business Update

Dicerna to Report First Quarter 2021 Financial Results on May 6, 2021

Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dicerna’s GalXC-Plus™ RNAi Technology Delivers Target Knockdown Across CNS and to Specific CNS Cell Types in Preclinical Studies

Dicerna to Present New GalXC-Plus™ Nonclinical CNS Data at Oligonucleotide and Precision Therapeutics Virtual Congress

Dicerna to Host Webinar on DCR-AUD Alcohol Use Disorder Candidate on March 18, 2021

Dicerna Announces Roche’s Initiation of GalXC™ RNAi Candidate RG6346 in Phase 2 Combination Trial for Treatment of Chronic Hepatitis B Virus Infection

Dicerna Announces Full Year 2020 Financial Results and Provides a Business Update

Dicerna to Participate in Upcoming Investor Conferences

Dicerna to Report Full Year 2020 Financial Results on Feb. 25, 2021

Dicerna Initiates PHYOX™4 Trial of Nedosiran for Primary Hyperoxaluria Type 3

Dicerna to Participate in the H.C. Wainwright Virtual BioConnect Conference

Dicerna Announces Novo Nordisk’s Nomination of First Candidate for Development Under RNAi Discovery and Development Agreement and Additional Milestone Achievement

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dicerna Announces Enrollment Completion of PHYOX™2 Pivotal Trial of Nedosiran for Treatment of Primary Hyperoxaluria

Year Published:

2021 2020 2019 2018

Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

Our mission

We interfere with disease

Effective 28 December 2021 Dicerna Pharmaceuticals, Inc. is a wholly owned subsidiary of Novo Nordisk A/S

Press Releases (2021)

Year Published:

2021 2020 2019 2018

Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

Our mission

We interfere with disease

Footer

Effective 28 December 2021 Dicerna Pharmaceuticals, Inc. is a wholly owned subsidiary of Novo Nordisk A/S